<DOC>
	<DOC>NCT00890591</DOC>
	<brief_summary>In patients naive to treatment or after a 2-week washout period for patients whose treatment was ineffective, the use of olmesartan was assessed in a 4-phase treatment scheme: monotherapy, addition of hydrochlorothiazide (2 phases), addition of amlodipine.</brief_summary>
	<brief_title>Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Angiotensin II Type 1 Receptor Blockers</mesh_term>
	<criteria>Stage 1 and 2 hypertension without treatment for at least 2 weeks Women with no risk of becoming pregnant Study participation could result in risk to health of subject Cardiovascular disease Secondary hypertension or stage 3 hypertension Myocardial infarction within the last 6 months Congestive heart failure Pulmonary edema Valvular alterations or rheumatic cardiopathy Clinically relevant conduction disorders significant arrhythmias Alcohol or illicit drug use Medication abuse Pregnant or nursing women</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>hypertension</keyword>
	<keyword>angiotensin II type 1 receptor blocker</keyword>
	<keyword>olmesartan</keyword>
</DOC>